Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
Filed with ASX · · 7 pages · English
Alterity Therapeutics Ltd. on 6ix
In the deck
Story so far
- Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
- Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
- Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Earlier from Alterity Therapeutics
- Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
- Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
- Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE
- Response to ASX Price Query
- Alterity Therapeutics to Provide Corporate Update in Fireside Chat
Later from Alterity Therapeutics
- Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
- Response to ASX Query Letters
- Appendix 4E and 2025 Annual Report
- Alterity Therapeutics to Present at the Biotech Showcase
- Trading Halt
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics